START-UP & ACADEMIC RATES AVAILABLE

May 22-24, 2019 | Boston, MA

www.microbiome-infant-health.com

MICROBIOME MOVEMENT MATERNAL & INFANT HEALTH

Discover & Translate Disease Causality of the Maternal-Infant Microbiome into Effective & Impactful Solutions To Improve Health in Early Life

Expert Speakers Including:

Jeff Roberts
Medical Officer
Division of Vaccines & Related Product Applications, OVRR/ CBER/FDA

Meghan Azad
Assistant Professor, Pediatrics & Child Health
University of Manitoba

Staffan Stromberg
CEO
Infant Bacterial Therapeutics

Nitya Jain
Principal Investigator
Harvard Medical School

Mark Heiman
CSO
Scioto Biosciences

Bethany Henrick
Director, Immunology & Diagnostic
Evolve BioSystems

Proud To Partner With:

Diversigen · LOOP GENOMICS · ProDigest Gastrointestinal Expertise · Paidion Research, Inc. Excellence in Pediatric Clinical Research

hansonwade

Tel: +1 617 455 4188 Email: info@hansonwade.com @MicrobiomeDaily

The Only Industry-Focused Forum Dedicated to Advancing Discovery & Translation of Disease Causality of the Maternal-Infant Microbiome into Effective & Impactful Solutions to Improve Health in Early Life

Compared to the development of microbiome-based products for adult disease, microbial-derived solutions for the pediatric setting have long been ignored. More recently, however, research investigating how the early life microbiome predisposes various health outcomes in infants is seeing an injection of scientific interest and investment.

As such, the inaugural ***Microbiome Movement* – Maternal & Infant Health Summit** has been established to improve your understanding of the maternal-infant microbiome mechanisms of action and advance translation of this causality into evidence-based, clinically validated therapeutic, nutritional and preventative solutions, which configure healthy foundations of the microbiome in the first 1000 days of life.

This is your opportunity to learn from the expertise of key opinion leaders from large pharma, biotech and academic research institutes presenting the latest case studies and in-depth discussion on key topics including:

- Discovering causal relationships between the maternal-infant microbiome and disease onset
- Exploring different therapeutic products that restore the infant microbiome, as well as treat and prevent disease
- Discussing study design for investigation of the microbiome in maternal and pediatric settings
- Understanding the role of the maternal microbiome in preterm birth and infant health outcomes
- Realizing how to integrate omics data with novel pre-clinical modelling to generate clinically meaningful results
- Explaining regulatory processes for IND-approved products targeting maternal and infant populations
- Addressing public health, economic and educational considerations for commercializing microbiome-based products for mothers and infants

There is no question that the pre-, peri- and postnatal maternal and infant microbiomes are critical windows of opportunity, that need to be acted upon today. Join us to unlock the therapeutic potential of the maternal-infant microbiome and contribute to healthier clinical outcomes in new-borns brought into the world tomorrow

Trish Kruk
Program Director
Microbiome Movement

Five Reasons to Attend

1.

Discover the current and future direction of the maternal-infant microbiome space with **Janssen Pharmaceutical companies of Johnson & Johnson**

2.

Explore cutting-edge research presented by the **Massachusetts General Hospital, University of Chicago & Harvard Medical School** in pursuit of causality between microbial-immune programming and disease onset

3.

Discover therapeutic approaches presented by **Infant Bacterial Therapeutics, ClosraBio & Scioto Biosciences** to treat allergy, prevent necrotizing enterocolitis and restore microbial balance

4.

Join **NC State University, the Aagard & Dominguez-Bello labs** to explore the role of the maternal microbiome in preterm birth and infant health

5.

Learn about navigating the regulatory landscape for microbiome-based therapeutics and delivering solutions to physicians, mothers and infants in need with the **FDA & Friedman School of Nutrition Science & Policy - Tufts University**

MEET THE EXPERTS

John Colson
Director of Operations
ClostraBio

Joseph Petrosino
CEO
Diversigen

Bethany Henrick
Director, Immunology & Diagnostic
Evolve BioSystems

David Kyle
Executive Chairman & CSO
Evolve BioSystems

Jeff Roberts
Medical Officer
Division of Vaccines & Related Product Applications, OVRR/CBER/FDA

Deshanie Rai
Associate Adjunct Professor
Friedman School of Nutrition Science & Policy - Tufts University

Noah Voreades
Consultant
GenBiome Consulting

Nitya Jain
Principal Investigator
Harvard Medical School

Staffan Stromberg
CEO
Infant Bacterial Therapeutics

Speaker TBC
Janssen Pharmaceutical Companies of Johnson & Johnson

Tuval Ben-Yehezkel
CEO
Loop Genomics

Alessio Fasano
Professor & Director Mucosal Immunology & Biology Research Center
Massachusetts General Hospital

Darrel Drinan
CEO
Natal Health

Ben Callahan
Assistant Professor
NC State University

Brian Kineman
Director of Clinical Sciences
Nestlé Nutrition North America (Gerber)

Devon Kuehn
CMO
Paidion Research, Inc.

Aurélien Baudot
International Business Developer
ProDigest

Keith Martinez
Post-Doctoral Fellow, Dominguez-Bello Lab
Rutgers University

Mark Heiman
CSO
Scioto Biosciences

Nikole Kimes
President, CSO & Co-Founder
Siolta Therapeutics

Cathryn Nagler
Bunning Food Allergy Professor
University of Chicago

Ryan Pace
Post-Doctoral Associate, McGuire Lab
University of Idaho

Meghan Azad
Assistant Professor, Pediatrics & Child Health
University of Manitoba

CONFERENCE DAY ONE
THURSDAY, MAY 23 2019

	7.30	**Registration & Morning Coffee**
	8.20	**Chairperson Opening Remarks**

Demonstrating Causality of Disease Induced by Infant Gut Dysbiosis

Introduction and Purpose:
Directed characterization of microbes in the infant microbiome has been central to understanding the functionality of microbes in both healthy and dysbiotic conditions. Whilst research has focused heavily on finding associations between the early-life gut microbiome and disease onset, the causality of these associations is less known. This theme will showcase new research demonstrating infant host-microbe interactions and causal pathways of the infant gut microbiome.

Speaker TBC
Janssen Pharmaceutical Companies of Johnson & Johnson

8.30 Current & Future Directions of the Maternal-Infant Microbiome & the First 1000 Days

Alessio Fasano
Professor & Director
Mucosal Immunology & Biology Research Center
Massachusetts General Hospital

9.00 Celiac Disease & Autism as Models to Show Causality Between Microbiome Composition/Function & Onset of Chronic Inflammatory Diseases (CID)

- Demonstrating the need for longitudinal birth cohort studies with robust datasets to establish causality between microbiome composition/function and disease onset
- Using celiac disease and autism as ideal models to show causality between infant microbiome and break of tolerance
- Understanding how to use robust metadata and multi-omic analysis to build mathematical models of disease to identify new therapeutic and/or preventive targets exploiting microbiome data

Cathryn Nagler
Bunning Food Allergy Professor
University of Chicago

9.30 Healthy Infants Harbour Intestinal Bacteria that Protect Against Food Allergy

- Outlining how germ free mice are colonized with bacteria from healthy, but not cow's milk allergic (CMA), infants are protected against anaphylactic responses to a cow's milk allergen
- Discussing how healthy and CMA colonized mice also exhibit unique transcriptome signatures in the ileal epithelium
- Identifying correlation of ileal bacteria with genes upregulated in the ileum of healthy or CMA colonized mice as butyrate producing Clostridial species, Anaerostipes caccae, that protects against an allergic response to food
- Demonstrating that intestinal bacteria are critical for regulating allergic responses to dietary antigens, suggesting that interventions that modulate bacterial communities may be therapeutically relevant for food allergy

Nitya Jain
Principal Investigator
Harvard Medical School

10.00 Microbial Influence of Early-Life Immune System Development

- Exploring how specific microbes and microbial products influence postnatal immune development
- Demonstrating how the host pattern recognition receptor, Toll-like Receptor 2, is one key mediator of crosstalk between microbes and the early-life developing immune system
- Focusing on distinct contributions of maternal and postnatal microbiota on offspring immunity

Defining Tools that Facilitate Microbial Characterization & Pre-Clinical Modelling to Improve Understanding of the Maternal-Infant Microbiome & Select Product Candidates for Further Development

Introduction and Purpose:

It has been difficult to fully characterize the dynamic nature of the maternal and infant microbiome, as well as to simulate *in vivo* conditions and interactions in the pre-clinical setting. As conventional pre-clinical tools are not entirely applicable for demonstrating host-microbe interactions, this theme will focus on tools being used to further our understanding of the infant gut microbiome and test product candidates.

Aurélien Baudot
International Business Developer
ProDigest

10.30 Baby-SHIME® Technology Platform: A Step by Step Approach for Pre-Clinical Product Testing on the Infant Gut Microbiome

- Introducing Baby-SHIME®: an in vitro simulation of the infant gastrointestinal tract
- Revealing efficient pre-clinical testing in a funnel approach: delivery, efficacy, long-term modulation
- Demonstrating the impact of HMOs on gut microbiota activity and composition

10.40 Speed Networking & Morning Refreshments

Tuval Ben-Yehezkel
CEO
Loop Genomics

11.40 Using Loop Genomics LoopSeqTM Single-Molecule Long-Read Sequencing to Characterize the Maternal & Infant Microbiome

- Outlining the LoopSeqTM synthetic long read sequencing technology that leverages existing Illumina short read sequencers coupled with LoopSeqTM barcoding technology to enable single-molecule, long-read sequencing on any Illumina infrastructure
- Exploring how this technology is applied to provide additional, previously inaccessible layers of information from Illumina sequencer for a wide variety of sequencing applications as diverse as Microbiome, Transcriptome, Targeted Amplicons and others

Understanding What 'Good' Looks Like - Examining the Gut Microbiome of Breast Fed Infants as a Reference Point

Introduction and Purpose:

The benefits of breast feeding are well established. However, questions remain around the influence of maternal diet on breast milk and how this shapes the infant microbiome and disease susceptibility. This theme will explore research focusing on what a 'good' infant microbiome looks like and how this can be used as a reference point to establish causality between microbial dysbiosis and disease.

Meghan Azad
Assistant Professor, Pediatrics & Child Health
University of Manitoba

11.50 Milk & Microbes in the CHILD Cohort: How Breastfeeding and Human Milk Shape the Infant Gut Microbiota and Influence Health Trajectories

- Highlighting how human milk has evolved to feed human infants and their gut microbiota, which supports optimal growth and development
- Understanding the process: we are studying the composition of human milk and fecal microbiota in the longitudinal CHILD cohort study of 3500 children followed since birth
- Using clinical data from the CHILD cohort to study the role of infant feeding practices and microbiota in the development of childhood asthma, allergies, and obesity

Key Considerations for Study Design Investigating the Role of the Maternal-Infant Microbiome in Birth & Infant Health Outcomes

Introduction and Purpose:

As more longitudinal approaches are taken to studying the maternal and infant microbiome, it is vital to establish best practices in conducting these studies. The aim of this panel is to discuss the key considerations for study design investigating the impact of the maternal and infant microbiome on birth and infant health outcomes.

Joseph Petrosino
CEO
Diversigen

12.20 Lessons from Longitudinal Studies of the Developing Gut Microbiome

- Identifying the benefits of longitudinal vs cross-sectional study of the microbiome
- Discussing optimal study design and hurdles in multi-cohort infant microbiome studies
- Addressing the main influences on the developing microbiome in infants/toddlers

12.50 Lunch & Networking

Devon Kuehn
CMO
Paidion Research, Inc.

13.50 Why Neonatal and Pediatric Clinical Trials Fall Short of Expectations

- Understanding limitations and nuances in these unique populations
- Ensuring study validity, quality, and compliance with regulatory requirements
- Harnessing lessons learned to overcome common trial execution challenges

Meghan Azad
Assistant Professor, Pediatrics & Child Health
University of Manitoba

Ben Callahan
Assistant Professor
NC State University

Nikole Kimes
President, CSO & Co-Founder
Siolta Therapeutics

14.00 Panel Discussion: Focusing on the Broader Challenges of Developing a Study Protocol

- What considerations are needed for analyzing the maternal and infant microbiome?
- How can we identify relevant mother and infant populations?
- How can we identify the consortia and alliances needed to get a study off the ground?

Exploring the Impact of the Maternal Microbiome on Pregnancy & Infant Health Outcomes

Introduction and Purpose:

Research has demonstrated associations between changes in the maternal microbiome throughout pregnancy with birth and infant health outcomes. However, the use of various methodological approaches towards measuring the impact of the maternal microbiome have resulted in incomparable findings. This session aims to explore studies focusing on understanding the role of the maternal microbiome during pregnancy, in preterm birth outcomes and in C-section birth.

Ben Callahan
Assistant Professor
NC State University

14.30 Composition of the Vaginal Microbiome is Predictive of Preterm Birth in Some Populations of Women

- Demonstrating that preterm birth can be predicted early in pregnancy from the vaginal microbiome in certain populations through replicated experiments
- Distinguishing sub-species variation within keystone taxa of the vaginal microbiome and how this determines association with preterm birth outcomes
- Revealing new high-resolution measurement technologies we have developed that discern sub-species variation and improve reproducibility between studies

Ryan Pace
Post-Doctoral Associate, McGuire Lab
University of Idaho

15.00 Exploring Species and Strain Ecology of the Vaginal Microbiome During Pregnancy and Postpartum

- Reviewing how permissiveness of the vaginal microbial community changes over time and with respect to pregnancy status
- Examining vaginal microbial taxa that are associated with mtDNA SNPs, which are co-associated with preterm birth outcomes
- Recognizing the pathobiont Group B Streptococcus as a prevalent, but low abundant, member of the vaginal microbiome

Keith Martinez
Post-Doctoral Fellow,
Dominguez-Bello Lab
Rutgers University

15.30 Restoration of Vaginal Exposure After C-Section Normalizes Body Weight

- Learning how C-section causes increased body weight in mice from weaning through adulthood
- Understanding how lack of vaginal exposure at birth leads to a lack in dynamic temporal changes in the gut microbiome
- Restoring vaginal exposure after C-section normalizes body weight and gut microbial communities

16.00 Afternoon Refreshments & Networking

Mastermind Session: Establishing Gold Standards for Study Design Investigating Microbiome-Based Products in Specific Maternal & Infant Populations

Introduction and Purpose:
This session will facilitate in-depth discussion amongst participants in an informal setting. After splitting into groups, participants will have the opportunity to discuss the study design, data and data analysis considerations needed for well-designed studies that demonstrate the safety and efficacy of microbiome-based products, in specific maternal and infant populations. Notes from this sessions will be shared with attendees after the meeting.

1. **16.30 Discussing study design for an LBT targeting necrotizing enterocolitis in preterm infants**

2. **16.30 Discussing study design for a microbiome-based product targeting the maternal microbiome to augment risk of disease onset in infancy**

3. **16.30 Discussing study design for a probiotic to be used as an infant formula ingredient or nutritional supplement**

17.10 Chairperson Closing Remarks

17.20 Close of Conference Day One

CONFERENCE DAY TWO
FRIDAY, MAY 24 2019

8.00 Registration & Morning Coffee

8.50 Chairperson Opening Remarks

Mobilizing Regulatory Guidance to Move Solutions Towards Approval & the Market Place

Introduction and Purpose:
Given the active engagement of US regulators with regards to live biotherapeutics in recent years, significant progress has been made in understanding the regulatory pathway and requirements for these products. This theme will provide a regulatory overview of considerations for microbiome-based products for pregnant women and in the pediatric setting.

Jeff Roberts
Medical Officer
Division of Vaccines & Related Product Applications, OVRR/CBER/FDA

9.00 Development of Live Biotherapeutic Products for use in Pregnant Women & Infants: U.S. Regulatory Perspective

- Understanding regulatory definitions and criteria, such as "drug", "live biotherapeutic (LBP)", and "substantial evidence of effectiveness"
- Outlining safety and risk mitigation in early phase development
- Addressing benefit-risk considerations that inform all phases of development and licensure application review

Therapeutic Interventions Targeting the Infant Microbiome to Restore Balance & Treat or Reduce Risk of Disease

Introduction and Purpose:
Whilst nutritional and preventative measures have been explored in the context of the adult human microbiome before, therapeutics targeting the infant microbiome are newcomers to the field. The purpose of this theme is to explore emerging products aiming to gain therapeutic regulatory approval and work to reverse dysbiosis in the infant gut microbiome.

Mark Heiman
CSO
Scioto Biosciences

9.30 Spontaneous Weaning of Rat Pups is Stimulated by SB-121 –mediated Gut Development

- Investigating SB-121: a novel live biological therapeutic designed for the neonate
- Demonstrating how SB-121 promotes development of a healthy functional gut
- Exploring how the development of healthy gut function permits weaning to solid food

John Colson
Director of Operations
ClostraBio

10.00 Microbiota-Derived Metabolites to Treat Food Allergy and Prevent Food Allergen Sensitivity

- Taking a novel approach to treat food allergies using polymer-modified bacterially-derived metabolites
- Exploring how ClostraBio's approach is informed by differences in the cow's milk allergic and healthy infant gut microbiota during the first 6 months of life
- Demonstrating how, in the context of dysbiosis and food allergy, ClostraBio's polymers are disease modifying and show potential to prevent allergic sensitization

10.30 Morning Refreshments & Networking

Staffan Stromberg
CEO
Infant Bacterial Therapeutics

11.30 Preventing Necrotizing Enterocolitis (NEC) in Premature Infants with IBT's Drug Candidate IBP-9414

- Outlining how IBT's IBP-9414 drug candidate prevents necrotizing enterocolitis (NEC) in premature infants
- Providing an industry perspective on the CMC and clinical considerations needed for testing a microbiome-based drug candidate in the infant setting
- Reflecting on lessons learned from developing a live biotherapeutic in the preterm infant setting

Focusing on Human Milk Oligosaccharides (HMOs) as an Influence on Immune & Metabolic Development in Early Life

Introduction and Purpose:
Infant formula continues to have a place in cases where mothers are unable or choose not to breast-feed. Understanding the composition of breast milk and the role of different components in infant growth has been pivotal in defining ingredients for infant formula and early life nutrition. This theme will explore the role of HMOs as an influence on immune and metabolic development in early life.

Brian Kineman
Director of Clinical Sciences
Nestlé Nutrition North America (Gerber)

12.00 Understanding the Role of Human Milk Oligosaccharides in Infant Nutrition

- Outlining how HMOs are different from the classic prebiotics
- Highlighting that HMOs bring health benefits to the host
- Understanding how HMOs shift the infant gut microbiome closer to the microbiome observed in breastfed infants

12.30 Lunch & Networking

David Kyle
Executive Chairman & CSO
Evolve BioSystems

13.30 Re-defining the Gold Standard... A Highly Functioning Infant Microbiome

- Reviewing how the infant microbiome is defined by its utilization of HMOs
- Highlighting key functions: pathogen deflection and mucous layer protection
- Addressing how immune education can be impacted be early gut microbiome
- Clarifying why the high functioning infant microbiome is on the verge of extinction

Addressing the Public Health, Economic & Educational Considerations for Commercializing Microbiome-Based Products for Infants & Mothers

Introduction and Purpose:
The economic burden of chronic diseases that develop over the life course is costing healthcare systems billions of US dollars. Additionally, as the public makes more choices with regards to health and wellness, it is vital to communicate the science, risks and benefits of microbiome-based products to consumers. This theme will allow reflection on the opportunity that lies in being at this early stage in understanding the maternal-infant microbiome, in shaping, influencing and defining the future of product development.

Deshanie Rai
Associate Adjunct Professor
Friedman School of Nutrition Science & Policy - Tufts University

Noah Voreades
Consultant
GenBiome Consulting

David Kyle
Executive Chairman & CSO
Evolve BioSystems

14.00 Panel Discussion: How Will the Future Horizons of Delivering Microbiome-Based Products into the Hands of Physicians and Mothers Change?

- What will it take for microbiome-based products to become products of choice for physicians and mothers?
- How can mechanism of action be effectively communicated to consumers to increase adoption?
- How can we ensure that products are used in the right settings?

Darrel Drinan CEO **Natal Health**	**14.40 Market Education – Mother and Clinician – Why Who and When?** • Addressing what education the market will need on the microbiome and the impacts to maternal and infant health • Discussing how to translate the clinical knowledge into consumer language and messaging • Understanding who the mother listens too – paediatrician, mommy blogger, peers, and/or family
Deshanie Rai Associate Adjunct Professor **Friedman School of Nutrition Science & Policy - Tufts University**	**15.10 Bridging the Gaps in Developing, Communicating and Commercializing the Scientific Relevance of the Microbiome in Early Life: Opportunities and Challenges** • Appreciating the relevance of the microbiome in early life and its influence on later life health outcomes, including economic impact and how to leverage this information to promote self-care through interventions • Understanding the importance of communication programs to help inform and educate health care professionals and consumers – how to achieve this within the guardrails of the regulatory environment • Implications for efficacious and safe product formulations to help bring the science to "life" – what's needed from the stakeholders?
	15.40 Chair's Closing Remarks
	15.50 End of Summit

"I am looking forward to hearing the progress leaders in the microbiome field are making, especially related to the positive impacts on the mom and infant health and growth"

Darrel Drinan, Natal Health, Confirmed Speaker

"This summit provides the ideal forum to connect cutting-edge research with commercial applications with specific focus on early development. I am particularly excited about the networking opportunities"

Brian Kineman, Nestlé Nutrition North America (Gerber), Confirmed Speaker

PRE-CONFERENCE WORKSHOP WEDNESDAY, MAY 22, 2019

Workshop A

Exploring Immune Education of the Gut During Early Life

13:00 – 16:00

As we strive to understand the causality of disease pathogenesis particularly in infanthood and early life, the role that the gut microbiome plays in educating the immune system has been given increased attention. This interactive workshop will give you the opportunity to have a deep dive into:

- What healthy immune modulation and induction of immunological tolerance looks like
- Autoimmune and atopic disease/condition manifestation over the life course
- The immune-gut microbiome interaction pathways implicated in inflammatory cytokine production

---

Workshop Leader

Bethany Henrick
Director, Immunology & Diagnostic
Evolve BioSystems

Bethany is an immunologist with extensive experience investigating maternal and infant immunity as well as a decade of experience designing, optimizing and bringing to market rapid point-of-care diagnostics focused on improving the lives of individuals globally. In addition to her position at Evolve Biosystems, Bethany also serves as an Adjunct Assistant Professor in the Food Science and Technology Department at the University of Nebraska Lincoln.



WHY PARTNER?

As our understanding of the adult microbiome is beginning to mature, maternal and infant microbiome research is seeing an injection of scientific interest and investment. Researchers and therapeutic developers are now on the look-out for the most innovative service providers with experience in microbial genome sequencing and analysis, *in vitro* and *in vivo* model provision, study design, contract manufacturing, as well as IP and regulatory consulting.

The inaugural ***Microbiome Movement* – Maternal & Infant Health Summit** is the perfect opportunity to demonstrate your technology, experience and capacity to meet the increasing demands of this emerging field.

Why Partner?

Benefit from Market Intelligence

Maternal and infant microbiome research opens opportunity to develop a range of preventative, nutritional or therapeutic products with applications in therapeutic contexts including metabolic, immune-related and neurocognitive diseases. Hear how and where biotech companies are looking for services and solutions to facilitate their R&D platforms and match your solutions accordingly.

Raise Brand Awareness

Benefit from pre and post conference exposure to our maternal-infant microbiome KOL community and increase market share through unique branding formats. Also, differentiate your discovery, pre-clinical and translational services from other solution providers.

Position Yourself as an Industry Expert

With the emergence of biotech companies focused on microbiome-based products for maternal and infant health, followed by interest shown from large pharma and investors, this meeting is a dedicated platform to put your independent expertise in front of the key decision makers in the field.

Meet and Network with Industry Pioneers

With a room full of microbiome-based product developers looking to see how they can effectively translate the maternal-infant microbiome into safe and effective therapeutics, meet prospective clients during speed networking breaks, 1-2-1 meetings and more informal networking receptions.

Generate Commercial Collaborations

Make sure your hottest prospects are in the room and part of the discussion, by having a wish-list of your choice contacted in advance of the event.

Seniority:



- **C-level**
- **President/ VP/Manager**
- **Director/ Manager**
- **Principal Scientist/ Lead Investigator**
- **Professor/ Associate Professor**

Company by Type:



- **Research Institute/ Healthcare Provider**
- **Venture Capitalist/ Investment Firms**
- **Equipment & Service Provider**
- **Microbiome-Based Product Developer**

* Statistics based on the *Microbiome Movement* - Drug Development Boston & Europe Summits 2017/8

> "This is great opportunity to learn and connect with thought leaders who are on the forefront in the emerging areas of maternal and infant microbiome health"
>
> **Noah Voreades, GenBiome Consulting, Confirmed Speaker**

Tel: +1 617 455 4188 **Email:** info@hansonwade.com
www.microbiome-infant-health.com @MicrobiomeDaily

hansonwade

PROUD TO PARTNER WITH

Expertise Partner

Diversigen

Accelerate and transform your research across the entire project lifecycle and capitalize on the diverse opportunities of the microbome. Diversigen provides comprehensive microbiome, metagenomics, host genetic services, customized study design, and complex data analysis – all focused on solutions to improve human and animal health, environmental conditions, and agriculture production worldwide.

www.diversigen.com

Innovation Partner

ProDigest
Gastrointestinal Expertise

ProDigest is a product leader in the development of unique laboratory models of the human and animal gastrointestinal tract (SHIME®). These models allow to obtain unique insight in gut processes associated to the intestinal fate of actives and to study the complete gut microbiome under controlled conditions.

www.prodigest.eu/en

Innovation Partner

LOOP GENOMICS

Loop Genomics is a DNA sequencing company with a vision to provide products that deliver the most complete and accurate drug development microbiome data. Loop technology meets the critical need for high-resolution phylogenetic data using long-read sequencing and single molecule abundance quantification, with an innovative approach that transforms existing short-read sequencing machines. Our long-read single-molecule microbiome sequencing products enable drug development R&D pipelines to discover previously inaccessible metagenomic information at unprecedented scale, while leveraging their existing sequencing systems and workflows.

www.loopgenomics.com

Innovation Partner

Paidion
RESEARCH, INC.
Excellence in Pediatric Clinical Research

Paidion Research, Inc. is a clinical research organization (CRO) focused exclusively on pediatrics and specializing in NICU and PICU populations (neonatal and pediatric intensive care). As a privately-held company located in the Research Triangle Park of North Carolina, Paidion combines expertise in pediatric regulatory strategy and pharmacometrics with excellent global clinical trial execution to create customized and innovative pediatric solutions to our partners. Learn how Paidion can successfully partner as your pediatric clinical research provider.

www.paidion.com

BECOME A PARTNER

Adam Haras-Gummer
Partnerships Director
The Microbiome Movement
E: adam.haras-gummer@hansonwade.com
T: +44 (0)20 3141 8727

JOIN THE MICROBIOME MOVEMENT

MICROBIOME MOVEMENT
DRUG DEVELOPMENT *Europe*

January 2019: Paris, FR
microbiome-europe.com

"The event organization and content was flawless. This is a premier event for the microbiome biotech and pharma industry."
Jim Brown, Senior Fellow Director in Computational Biology, GSK

MICROBIOME MOVEMENT
AGBIOTECH

February 2019: Raleigh, NC
microbiome-agbiotech.com

"Possibly the best conference in the agricultural microbiome space - a great mix of basic scientific research and product development from universities, multinationals and start-up companies. Congratulations!"
Marcus Meadows-Smith, CEO, BioConsortia

MICROBIOME MOVEMENT
MATERNAL & INFANT HEALTH

May 2019: Boston, MA
microbiome-infant-health.com

"This is great opportunity to learn and connect with thought leaders who are on the forefront in the emerging areas of maternal and infant microbiome health"
Noah Voreades, GenBiome Consulting, Confirmed Speaker

MICROBIOME MOVEMENT
DRUG DEVELOPMENT

June 2019: Boston, MA
microbiome-summit.com

"This meeting is possibly the best in the microbiome field for a biotech company, for networking and hearing the latest developments."
Mike Romanos, CEO, Microbiotica

MICROBIOME MOVEMENT
SKIN HEALTH & DERMATOLOGY

September 2019: San Diego, CA
microbiome-dermatology.com

"This meeting was the perfect balance between basic/ applied science and academic/commercial interests."
Greg Hillebrand, Senior Principal Research Scientist, Amway

MICROBIOME MOVEMENT
ANIMAL HEALTH

October 2019: St. Louis, MO
microbiome-animal.com

"I really enjoyed meeting critical innovators within Animal Health and learn more about how technologies within this space and developing and the key problems being addressed."
Megan Lyman, Director, IP, Regulatory & Product Development, AgTech Accelerator

MICROBIOME MOVEMENT
HUMAN NUTRITION

November 2019: Boston, MA
microbiome-nutrition.com

"If you want to learn about the latest developments and mix with the movers and shakers in the industry, you HAVE to be there."
Alan Murray, CEO, NextFoods Inc

MICROBIOME MOVEMENT
GUT-BRAIN AXIS

December 2019: Boston, MA
gutbrain-axis.com

"It is one of the best meeting I've been to! Great job!"
Yanjiao Zhou, Research Scientist, The Jackson Laboratory

THE PROMISE OF THE MICROBIOME MOVEMENT

Dear Microbiome Enthusiast,

As the knowledge of the microbiome continues to deepen, fundamental understanding of mechanism of action and demonstrating causality continue to improve. As such, *The Microbiome Movement* has become more committed than ever to work alongside innovative researchers and industry leaders to build events that focus on applied science and translate cutting-edge microbiome R&D into safe, effective and commercially successful products across a number of industry-specific verticals.

Positioned at the heart of pharmaceutical, agricultural, nutritional and animal health R&D, *The Microbiome Movement* continues to help accelerate the discovery, development and delivery of breakthrough solutions to global challenges to benefit human health. For each specific industry where the microbiome will have a real impact, we're building an exclusive community for you to maximize the opportunity.

We build every event from six key pillars to make sure everything you read, watch and experience will truly help you gain better insight and ultimately help drive the microbiome community together.

This is our promise to you.

Passion

We love this space and believe in its long term impact, and we know you do too

Integrity

Showcasing only the most cutting-edge and scientifically validated research, data and best practice into our programs

Quality

Deep market research allows us to cut through the noise and share relevant insights that are important to you

Specificity

Each event agenda is independently designed and curated with a clear narrative to suit your industries' needs

Originality

Adapting with a fast growing community to accelerate your research across healthcare, agriculture and beyond

Trail-Blazing

Staying one step ahead of the latest opportunities and trends, to keep you informed and help make better commercial decisions

We really hope you can join us on this journey and be a part of the microbiome revolution.

Long Live The Microbiome!

Trish Kruk
Program Director
The Microbiome Movement

3 EASY WAYS TO BOOK

www.microbiome-infant-health.com

Tel: +1 617 455 4188

Email: register@hansonwade.com

TOP 3 REASONS TO ATTEND:

1. Discover pioneering data-driven case studies that showcase the latest pre-clinical data supporting causality between the maternal-infant microbiome and disease onset
2. Debate pediatric-specific study design challenges with your peers and competitors
3. Uncover and forge the collaborations you need to develop effective and commercially successful microbiome-based interventions for infants and mothers

SECURE YOUR PLACE

Industry Pricing	Register & Pay By Thursday, April 18	Standard Pricing
Conference + Workshop	$2698 **(save $300)**	$2898 **(save $100)**
Conference Only	$2199 **(save $200)**	$2399
Workshop Only	$599	

Academics & Not-For Profit Pricing	Register & Pay By Thursday, April 18	Standard Pricing
Conference + Workshop	$1798 **(save $300)**	$1998 **(save $100)**
Conference Only	$1499 **(save $200)**	$1699
Workshop Only	$399	

Team Discounts

Maximize value for money using special team discounts:

- **10% discount – 2 delegates**
- **15% discount – 3 delegates**
- **20% discount – 4+ delegates**

Please note that discounts are only valid when two or more delegates from one company book and pay at the same time. Group discounts cannot be used in conjunction with other discount codes or offers, other than the early booking rates.

For more information on group discount eligibility, rates and booking, please contact: register@hansonwade.com

*** Please note we have a special rate of $599 for students and post-docs.**

To find out more information, please email info@hansonwade.com. Full T&Cs apply. Visit the website for full eligibility criteria.

VENUE

The Revere Boston Common Hotel
200 Stuart Street, Boston
Massachusetts 02116

For further information or assistance, please visit www.reverehotel.com

Code: 13005